In addition, multiple clinical studies in medullary thyroid carcinoma, melanoma, breast, ovarian, and prostate cancer have shown a direct correlation between serum CXCL8/IL-8 levels and disease progression [65, 66]. Here, CXCL8 is linked to melanoma.